AngioDynamics (NASDAQ: ANGO) Beats Q2 FY26 Estimates, Raises Guidance. Stock Dips 14%. Buy the Pullback?

AngioDynamics just reported Q2 fiscal 2026 earnings, beating both revenue and EPS expectations and raising full-year guidance. Key takeaways: • Revenue: $79.4M (+8.8% YoY, beat estimates) • Adj. EPS: $0.00 (vs. −$0.22 expected) • FDA wins: IDE approval (PAVE study) + 510(k) for AlphaVac • FY26 sales guidance raised to $312–314M • Strong Med Tech growth (Mechanical Thrombectomy, NanoKnife, Auryon) Despite this, the stock dropped −14% following leadership transition news. Analysts still rate ANGO a Strong Buy, with avg target $19.33 (\~63% upside). Full breakdown: [https://dexwirenews.com/angiodynamics-ango-q2-fiscal-2026-earnings-stock-buy-after-40-percent-rally/](https://dexwirenews.com/angiodynamics-ango-q2-fiscal-2026-earnings-stock-buy-after-40-percent-rally/) Question: Is this an overreaction or a warning sign?